Table 1.
Neurological manifestations of post-COVID.
| Study Parameters | Huang et al. [39] | Zhang et al. [38] | Graham et al. [21] | Pilotto et al. [42] | Woo et al. [27] |
|---|---|---|---|---|---|
| Time from onset, months | 6.2 (5.8–6.6) | 12.0 (11.9–12.4) | 5.3 (3.4–6.4) | 6 | 2.8 (0.7–3.5) |
| Sample size | 1733 | 2433 | 100 | 165 | 18 |
| Male/female (%) | 52/48 | 49.5/50.5 | 70/30 | 69.7/30.3 | 56/44 |
| Age, years | 57.0 (47.0–65.0) | 60.0 (49.0–68.0) | 43.2 (11.3) | 64.8 ± 12.6 | 42.2 (14.3) |
| Mild/severe COVID-19 (%) |
25/75 | 72.1/27.9 | 100/0 | 34.5/65.5 ** | 100/0 |
| Neurological symptoms | |||||
| “Brain fog” | N/R | N/R | 81% | N/R | N/R |
| Headache | 2% | 2.3% | 68% | 9.7% | N/R |
| Myalgia | 2% | 7.9% | 55% | 29.6% | N/R |
| Fatigue | 63% | 27.7% | 85% | 34% | 16.7% |
| Anosmia/hyposmia | 11% | 1.3% | 55% | 18% | N/R |
| Dysgeusia/hypogeusia | 7% | 1.4% | 59% | 18% | N/R |
| Mental disorders | |||||
| Insomnia | 26% | N/R | 33% | 30.8% | N/R |
| Depression/Anxiety | 23% | 10.4% | 47% | 26.7% | 11.1% * |
| Memory deficit | N/R | N/R | 32% | 31% | 44.4% |
| Attention deficit | N/R | N/R | 27% | 31% | 50% |
* Severe mood swing. ** Mild/moderate + severe COVID-19. N/R—not reported.